Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
64.75
+0.90 (+1.41%)
Streaming Delayed Price
Updated: 12:24 PM EDT, Jun 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
24
25
26
27
28
29
30
31
Next >
NRXP Stock Alert: What Is Going on With NRx Pharmaceuticals Today?
December 29, 2021
NRx is seeking breakthrough designation for its treatment based on new, favorable data on the drug. NRXP stock is climbing on the news.
Via
InvestorPlace
Pfizer's CEO Shows You How To Get 'Impossible' Tasks Done Fast
December 29, 2021
Scientists told the Pfizer CEO they could create a vaccine in 18 months. But Albert Bourla knew they could work even faster.
Via
Investor's Business Daily
Mobile Clinics for Mental Health Treatments Reportedly Launching in Major Cities Across the U.S.
December 28, 2021
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...
Via
Benzinga
Best Stocks For Wheel Strategy Trades: Use These In 2022
December 26, 2021
Blue chips companies, high dividend stocks, REITs, and low beta ETFs work well when employing the wheel strategy.
Via
Talk Markets
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
December 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug...
Via
Benzinga
Gilead's Remdesivir Shows Consistent Efficacy In Patients With Comorbidities With Higher Risk for Severe COVID-19
December 23, 2021
Gilead Sciences Inc (NASDAQ: GILD) announced full results from a Phase 3 study of a three-day course of Veklury (remdesivir) non-hospitalized COVID-19 patients at...
Via
Benzinga
Price To Earnings Ratio Insights For Gilead Sciences
December 22, 2021
In the current market session, Gilead Sciences Inc. (NASDAQ:GILD) is trading at $70.76, after a 1.50% decrease. However, over the past month, the stock went up by 0.98%,...
Via
Benzinga
FDA Slaps Clinical Hold On Gilead's Injectable Lenacapavir In HIV Trials
December 22, 2021
The FDA has placed a clinical hold on Gilead Sciences Inc's (NASDAQ: GILD) injectable lenacapavir in borosilicate vials in all ongoing clinical studies...
Via
Benzinga
The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda
December 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With...
Via
Benzinga
European Commission Expands Use Of Remdesivir In COVID-19 Patients Not On Supplemental Oxygen
December 21, 2021
The European Commission (EC) has approved a variation to the Conditional Marketing Authorization for Gilead Sciences Inc's (NASDAQ: GILD) Veklury (...
Via
Benzinga
EMA Might Not Decide On Merck's COVID-91 Oral Antiviral Before Christmas: Reuters
December 17, 2021
The EU drug regulator might not decide whether to approve Merck & Co Inc's (NYSE: MRK) molnupiravir, COVID-19 antiviral until after Christmas, a source with...
Via
Benzinga
Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients
December 14, 2021
Kite Pharma, a Gilead Science Inc company (NASDAQ: GILD), churned out more data for its CAR-T Yescarta in first-line lymphoma patients. The Company...
Via
Benzinga
Gilead's Kite Unveils More Data On Yescarta In Second-Line Lymphoma Patients
December 13, 2021
Kite Pharma, a Gilead Science Inc's Company (NASDAQ: GILD), announced primary analysis results from the ZUMA-7 Phase 3 trial of Yescarta (axicabtagene...
Via
Benzinga
Why Arcus Biosciences Stock Vaulted Higher in November
December 09, 2021
Arcus was one of the few winners in the turbulent biotech space last month.
Via
The Motley Fool
Is Gilead Sciences Stock a Buy Now?
December 07, 2021
Gilead Sciences is facing multiple headwinds, but there may be hope for the biotech company.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
December 09, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:
Via
Benzinga
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
December 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021
December 06, 2021
Upgrades According to TD Securities, the prior rating for MAG Silver Corp (AMEX:
Via
Benzinga
Gilead Recalls Two Lots Of Remdesivir Due To Presence Of Glass Particulates
December 06, 2021
Gilead Sciences Inc (NASDAQ: GILD) has issued a nationwide recall of two lots of its COVID-19 treatment drug Remdesivir because of the presence of glass...
Via
Benzinga
Topics
Product Recall
Exposures
COVID-19
Legal
Product Safety
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
December SPAC Merger Calendar: Upcoming Votes, Stocks To Watch
December 05, 2021
The month of December shows an increasing number of SPAC deal votes. SPAC merger votes can act as a catalyst, as the votes complete the last step in the merger process and change...
Via
Benzinga
Got $1,000? Check Out These 3 Top Biotech Stocks
December 03, 2021
Two big biotechs and one smaller one that could be winners over the long term.
Via
The Motley Fool
Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail?
November 29, 2021
Smaller companies are working on next-generation approaches to Covid treatment.
Via
Investor's Business Daily
Why Are NRx Pharma's Shares Soaring Premarket?
November 29, 2021
NRx Pharmaceuticals (NASDAQ: NRXP) has completed an analysis in the subgroup of Zyesami and placebo-treated patients previously treated with Gilead Science Inc's...
Via
Benzinga
3 Dividend Stocks That Are Dirt Cheap Right Now
November 25, 2021
If you want dividend growth, dividend safety, and an undervalued stock, these three fit the bill.
Via
The Motley Fool
A Look Into Gilead Sciences Debt
November 24, 2021
Shares of Gilead Sciences (NASDAQ:GILD) fell by 1.76% in the past three months. Before we understand the importance of debt, let us look at how much debt Gilead Sciences...
Via
Benzinga
Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial
November 24, 2021
Gilead Sciences Inc (NASDAQ: GILD) and Merck & Co Inc (NYSE: MRK) have temporarily paused enrollment in the Phase 2 study evaluating the combination...
Via
Benzinga
Gilead's Trodelvy Approved In Europe For Aggressive Form Of Breast Cancer
November 23, 2021
The European Commission has approved Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan) as monotherapy for triple-negative breast cancer (...
Via
Benzinga
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
November 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In...
Via
Benzinga
Exposures
COVID-19
Product Safety
Next Week Trading Opportunities - GILD, ETSY, FCEL, PLUG, SNOW, AAPL
November 21, 2021
With the assistance of AI we can identify patterns, trends, and buy/sell signals. Here are the prospects in the coming week for these six stocks.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
< Previous
1
2
...
24
25
26
27
28
29
30
31
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.